Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB (MEDI4736) in Advanced HER-2 Negative Breast Cancer: a Pilot Proof-of-concept Trial

NCT02802098 is registered in ClinicalTrials.gov with Centro Nacional de Investigaciones Oncologicas CARLOS III as lead sponsor.

NCT NCT02802098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02802098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB (MEDI4736) in Advanced HER-2 Negative Breast Cancer: a Pilot Proof-of-concept Trial
Lead sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
July 31, 2019
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bevacizumab-alone maintenance treatment progression, metastatic breast cancer